Key result
Cisplatin-based chemotherapy is linked to ~90% greater CV risk in testicular cancer survivors.
Why the study?
Cisplatin-based chemotherapy cures testicular germ cell tumors and yields normal life expectancy, but long-term detection in plasma and urine raises concerns about late cardiovascular complications.
Does cisplatin-based chemotherapy increase the risk of cardiovascular disease in testicular germ cell tumor survivors?
Does cisplatin-based chemotherapy increase the risk of cardiovascular disease in testicular germ cell tumor survivors?
Testicular cancer survivors treated with cisplatin-based chemotherapy require lifelong cardiovascular risk screening and management due to an elevated long-term risk of cardiovascular complications.
No takes yet. Share an insight, caveat, or question.
May support enhanced CVD vigilance in survivors; leaves open optimal screening and prevention strategies.
Alizadehasl et al. (2023) conducted a review in Testicular germ cell tumors. Cisplatin-based chemotherapy vs. General population was evaluated. Cisplatin-based chemotherapy regimens in testicular cancer survivors increase the risk of cardiovascular disease compared to the general population by up to 1.9-fold (95% CI 1.7-2.0).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: